NUKKing ‘em
DENVER, Colo., Dec 18, 2024 (247marketnews.com)- Siyata Mobile (NASDAQ: SYTA), Cognition Therapeutics (NASDAQ: CGTX), Polyrizon (NASDAQ:PLRZ), Nukkleus (NASDAQ: NUKK), Quantum Computing (NASDAQ: QUBT), and Rigetti Computing (NASDAQ: RGTI)
Siyata Mobile (NASDAQ: SYTA) closed its first major order for a prominent national Dutch transportation company, a significant international expansion milestone.
Marc Seelenfreund, Siyata Mobile’s CEO, stated, “This order underscores the increasing recognition of our innovative PoC solutions outside of North America. While the U.S. remains a primary focus, our ability to secure a significant contract in The Netherlands illustrates the international appeal of our technology. It’s a strong testament to Siyata’s capability to address the evolving communication needs of enterprise customers worldwide. By replacing traditional two-way radios, our PoC devices offer superior coverage, enhanced audio clarity, and cost efficiency—benefits that resonate globally.”
Siyata previously announced that it will host an upcoming press event to showcase a new significant material development, which is tentatively scheduled for late December 2024, about which Seelenfreund emphasized, “Siyata is in the best position it’s been in since our company’s inception, as our capital expenditures have directly improved all performance metrics, and we look forward to delivering continued successful results. Please tune into our upcoming press conference, which will highlight a next level shareholder value creation event that you surely won’t want to miss.”
Cognition Therapeutics (NASDAQ: CGTX) reported positive topline results from the exploratory Phase 2 ‘SHIMMER’ study demonstrating that CT1812 produced strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with dementia with Lewy bodies (DLB).
James E. Galvin, MD, MPH, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and a principal investigator in the SHIMMER study, stated, “The results from this exploratory Phase 2 trial demonstrated CT1812 could have a meaningful, positive impact on DLB patients across multiple measures of cognitive, behavioral, movement, and functional performance. DLB is a multifactorial disease where patients experience a constellation of symptoms, and the results of this study suggest CT1812 holds promise for DLB patients and their care providers. I believe the SHIMMER topline results are both exciting and very promising, and I am looking forward to working with the team at Cognition as they determine the appropriate next steps for CT1812.”
Polyrizon (NASDAQ:PLRZ) is one of the morning’s most active listings following its reiteration of previously announced news that it entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine, which will supply Clinical Trial Material (CTM) for Polyrizon’s PL-14 allergy blocker, in preparation for a clinical trial that is expected to commence in 2025.
Tomer Izraeli, Polyrizon’s CEO previously stated, “We are pleased to have established this partnership with Eurofins CDMO Amatsiaquitaine S.A.S, which strengthens our preparation efforts for the upcoming PL-14 clinical trial. We believe that this collaboration marks a significant milestone in our journey toward providing effective allergy protection solutions to patients.”
Nukkleus (NASDAQ: NUKK) published a correction to yesterday’s announcement of its successful acquisition of a 51% controlling stake in Star 26 Capital Inc., a defense acquisition company holding 95% ownership in RIMON, a leading Israeli supplier of components for the Iron Dome missile defense system, as well as other defense and tactical solutions.
Manny Shalom, CEO of Nukkleus, stated, “This merger positions Nukkleus at the forefront of a booming defense industry. Our acquisition of Star 26 and RIMON aligns with our strategic pivot to capitalize on opportunities in the defense sector, which has seen rapid growth due to geopolitical shifts in the Middle East and the war in Ukraine. This has resulted in a surge of investments and acquisitions in Israeli defense firms such as PARAGON and PROTEGO, alongside a 120% increase in Israel’s defense indices and a 38% rise in similar indices in the US.”
Quantum Computing (NASDAQ: QUBT) is another listing that’s following through news from yesterday, when it reported that it was awarded a prime contract by the National Aeronautics and Space Administration’s (“NASA”) Goddard Space Flight Center, marking a pivotal step forward for QCi, by applying its entropy quantum optimization machine, Dirac-3, to support NASA’s advanced imaging and data processing demands.
Dr. William McGann, QCi’s CEO, commented, “QCi is proud to support NASA in this critical mission to process large volumes of interferometric imaging data more efficiently. The project’s goal is to demonstrate how QCi’s Dirac-3 can address the phase unwrapping problem and allow NASA to compare the results and benefits of QCi’s quantum optimization technology with state-of-the-art algorithms running on classical computers.”
Mobot alerted Rigetti Computing (NASDAQ: RGTI) in October at $0.926 and last week’s news that it successfully applied AI to automate the calibration of a quantum computer with Quantum Machines has provided additional fuel to its impressive run.
Please go to 247marketnews.com to sign up for free MoBot alerts and view Mobot’s real time data.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (SYTA, CGTX, PLRZ, NUKK, QUBT, RGTI)
- Quantum Computing Inc. Announces Closing of Oversubscribed Private Placement of Common Stock for Proceeds of $500 Million
- Quantum Computing Inc. Announces $500 Million Oversubscribed Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
- Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker
- 24/7 Market News Snapshot 19 September, 2025 – Polyrizon Ltd. Ordinary Shares (NASDAQ:PLRZ)
- Morning Market Snapshot: ZOOZ Goes Full Bitcoin, VENU Turns Up the Volume, and Eyes Turn Toward Quantum Movers